[CITATION][C] Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
WJ van Heeckeren, J Ortiz, MM Cooney… - Journal of clinical …, 2007 - europepmc.org
WJ van Heeckeren, J Ortiz, MM Cooney, SC Remick
Journal of clinical oncology: official journal of the American Society …, 2007•europepmc.orgHypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical
toxicity, therapeutic target, or novel biomarker? - Abstract - Europe PMC Sign in | Create an
account https://orcid.org Europe PMC Menu About Tools Developers Help Contact us Helpdesk
Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus Search life-sciences
literature (41,988,656 articles, preprints and more) Search Advanced search Feedback This
website requires cookies, and the limited processing of your personal data in order to …
toxicity, therapeutic target, or novel biomarker? - Abstract - Europe PMC Sign in | Create an
account https://orcid.org Europe PMC Menu About Tools Developers Help Contact us Helpdesk
Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus Search life-sciences
literature (41,988,656 articles, preprints and more) Search Advanced search Feedback This
website requires cookies, and the limited processing of your personal data in order to …
This is a comment on" Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors." J Clin Oncol. 2007 Jul 20; 25 (21): 3045-54.
europepmc.org
